Navigation Links
EntreMed Reports First Quarter 2012 Financial Results
Date:5/15/2012

pharmaceutical company committed to using global resources to develop its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently completing a multi-center Phase 2 study in ovarian cancer and completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including:  the risk that we may be unable to co
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HAMILTON, N.J. , Oct. 22, 2014 ... CLIA-certified, CAP-accredited laboratory which specializes in high ... that it is now offering new Cystic ... including next- generation DNA sequencing platforms. ... a genetically inherited multisystem disorder that affects ...
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... May 11, 2012  Amgen (NASDAQ: AMGN ) ... vice president of Research and Development at Amgen will ... Administration (FDA) stakeholder hearing on biosimilars. Miletich will urge members ... for biosimilars to establish approval standards that advance patient ...
... Mylan Inc. (Nasdaq: MYL ) today ... mg, 20 mg, 40 mg and 80 mg in ... has received marketing authorization from each country,s respective health ... is the generic version of Pfizer,s Lipitor® Tablets. This ...
Cached Medicine Technology:Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 2Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 3Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 4Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 5Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 6Mylan Launches Generic LipitorĀ® in Five European Countries 2
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... 25, 2014 Limbkeepers® announced today that ... Innovations with Ed Begley Jr, airing 1st QTR 2015 ... In this episode, Innovations will focus on Limbkeepers® non ... fragile, thinning skin on arms, hands, and legs from ... these versatile products, which help reduce injuries, allow for ...
(Date:10/25/2014)... By Steven Reinberg ... -- The virus that causes common cold sores -- herpes ... studies by Swedish researchers suggest. In fact, being a ... risk of Alzheimer,s disease, the researchers found. "The ... common dementia disorder is a breakthrough," said lead researcher Dr. ...
(Date:10/25/2014)... -- Researchers who discovered antibiotics in farmed and ... concern. The use of antibiotics in animals, ... contribute to the development of antibiotic-resistant bacteria that ... the study. Each year in the United ... and kill about 23,000, according to the Infectious ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... home importance of awareness and,education of kidney disease, which ... Calif., Oct. 16 In a nationwide,effort to raise ... focusing on raising awareness of kidney disease among 20 ... the nation,s,largest independent dialysis provider, announced today that its ...
... A small capsule that takes snapshots of the small ... doctors spot cases of Crohns disease that had gone ... at Wake Forest University Baptist Medical Center. , Reporting ... in Philadelphia, the researchers said that of 198 video ...
... leading provider of,Business Process Integration solutions for ... filled three Director-level positions based at the,company,s ... Thompson,Director of Data Management; Darryl Means, Director ... Healthcare Operations. (Logo: http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) ...
... ... Oct. 16 With the percentage of,overweight American children and ... milk?" Milk Mustache Campaign is recognizing 10,pediatricians across the nation ... obesity crisis into their own hands. Since 1991, the ...
... When you are healthy,purchasing disability insurance can ... financial asset: your,ability to earn a living, says ... care insurance lawyer. (Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02 ... you want to make sure you,buy the right ...
... ROCHESTER, N.Y., Oct. 16 Many routine surgical ... dermatologists may soon be sharing,reviewing and diagnosing noninvasive ... Lucid Inc.,s VivaNet(TM) telemedicine server and its,VivaScope(R) confocal ... special microscopes to digitally,image a patient,s skin, may ...
Cached Medicine News:Health News:DaVita Volunteers Raise More than $1,000,000 for Nationwide Kidney Education and Prevention Programs 2Health News:Capsule endoscopy turning up undiagnosed cases of Crohn's disease 2Health News:Three New Director-Level Appointments at Adaptis 2Health News:Three New Director-Level Appointments at Adaptis 3Health News:Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity 2Health News:Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity 3Health News:Pediatricians Awarded for Innovative Approaches to Combat Childhood Obesity 4Health News:Why Healthy People Should Consider Individual Disability Insurance 2Health News:VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients 2
Bench Top Horizontal (clean bench) Airflow Cabinet...
... chamber provides a safe, clean environment ... in accord with USP-797 requirements. HEPA ... 5) cleanliness conditions in the work ... and tilt-up front panel for easy ...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
... and removes chemical fumes, allowing ... Bonded charcoal filters remove most ... safe exhaust flow speed = ... opening. Includes air speed monitor, ...
Medicine Products: